Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease.

ABSTRACT:

Background

We investigated whether a panel of 12 potential novel biomarkers consisting of proteins involved in synapse functioning and immunity would be able to distinguish patients with Alzheimer's disease (AD) and patients with mild cognitive impairment (MCI) from control subjects.

Methods

We included 40 control subjects, 40 subjects with MCI, and 40 subjects with AD from the Amsterdam Dementia Cohort who were matched for age and sex (age 65 ± 5 years, 19 [48%] women). The mean follow-up of patients with MCI was 3 years. Two or three tryptic peptides per protein were analyzed in cerebrospinal fluid using parallel reaction monitoring mass spectrometry. Corresponding stable isotope-labeled peptides were added and used as reference peptides. Multilevel generalized estimating

SUBMITTER: Duits FH 

PROVIDER: S-EPMC6389073 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature